Transnetyx, Inc.

Transnetyx, Inc., headquartered in Cordova, Tennessee, delivers automated genotyping, DNA extraction, multi-gene analysis, and bioinformatics services to federal biomedical research institutions as a prime contractor across 278 awards, competing exclusively in full-and-open procurement without set-aside designations. The company operates as a for-profit entity with three named subsidiaries (Laragen Holdco LLC, A-Tune Software Inc., and Brainbits LLC) and maintains a narrow, specialized capability footprint centered on laboratory genetic testing and animal colony management services for transgenic rodent research models.

Transnetyx's customer base concentrates heavily within the Department of Health and Human Services National Institutes of Health ecosystem. The top five funding components—the National Institute of Environmental Health Sciences (37 awards, $29.8 million combined potential value), the Office of Logistics and Acquisition Operations (11 awards, $11.9 million), the National Institute on Aging (13 awards, $6.2 million), the National Institute on Arthritis and Musculoskeletal and Skin Diseases (11 awards, $1.3 million), and the National Institute on Drug Abuse (75 awards, $1.1 million)—account for approximately 94 percent of the company's combined potential value and 60 percent of its award count. The National Institute on Drug Abuse ranks first by volume but ranks fourth by dollar value, indicating it places numerous small orders; by contrast, NIEHS anchors most of the revenue through fewer, larger vehicles. The vendor also maintains relationships with the Department of Veterans Affairs (multiple VISNs), the Food and Drug Administration, and the National Center for Complementary and Integrative Health, among other agencies.

Transnetyx operates four primary parent vehicles. A Blanket Purchase Agreement with the NIH National Institute of Biomedical Imaging and Bioengineering (HHSN263201100002B) carries 130 task orders valued at $2.2 million combined. A $10 million Blanket Purchase Agreement with the Office of Logistics and Acquisition Operations (non-set-aside, O/M items limited to laboratory and testing supplies, expiring October 31, 2026) has generated substantial call volume. The company also holds a single-award Indefinite Delivery Contract with the National Institute on Aging for the NIA Genotyping Outsourcing Project, valued at $1,696,320 through April 3, 2031, which provides DNA extraction and multi-gene analysis of rodent tissue samples with 72-hour turnaround requirements; this vehicle has generated delivery orders including one for $366,420 (April 2026 base-year award) and another for $298,718 (May 2022 base-year award). A second NIA IDC valued at $1,465,680 (ultimate completion April 3, 2026) also funded multi-year genotyping outsourcing work. Transnetyx holds a $375,000 single-award indefinite-delivery contract with the Department of Veterans Affairs Veterans Integrated Service Network 21 (June 24, 2025, through June 23, 2030) for automated genotyping services at the San Francisco VA Healthcare System, with delivery orders already placed for $75,000 (FY2026) and $75,000 (FY2027).

Recent representative work includes a $176,712 purchase order from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (August 17, 2026, non-severable genotyping analysis), a $1,080,000 delivery order from the National Institute of Environmental Health Sciences (September 14, 2025, through September 11, 2026, genotyping services), a $341,380 purchase order from the National Institute of Allergy and Infectious Diseases (February 1, 2026, mouse genotyping and genetic monitoring), a $115,200 Total Small Business set-aside purchase order from the Department of Veterans Affairs Veterans Integrated Service Network 16 (September 16, 2024, qPCR genotyping of transgenic mice, extending through September 15, 2029), and a $1,200,000 delivery order from NIEHS (September 14, 2024, through September 13, 2025, with subsequent descoping under Executive Order 14042 cost-efficiency initiative).

The vendor operates as a 100 percent prime contractor with no subcontractor engagement across its portfolio, indicating it builds its own delivery capacity and does not routinely partner with or feed into larger prime teams. Activity has grown from 17 awards in 2022 to a peak of 35 in 2024, moderating to 31 in 2025 and 10 year-to-date in 2026 (through mid-August). Thirteen awards with ultimate completion dates in the next twenty-four months carry combined potential value of $2.3 million and face near-term recompete exposure. SCI-reportable invoiced revenue shows $1.2 million in FY2022 across an unusually high FTE allocation (2,861 FTEs), but FY2023 and FY2024 show zero SCI invoicing; FY2025 shows 31.3 FTEs across 3 prime records, suggesting significant non-SCI revenue (goods, micro-purchases, or amounts below the $150,000 reporting threshold) comprises most of the company's federal revenue stream. Median government-paid hourly rates on SCI-reportable records remain at $0.21 per hour, a rate structure consistent with pass-through laboratory testing or materials costs rather than professional services labor billing.

Transnetyx has been registered in the System for Award Management since 2007, serving as a specialized genetic testing vendor to NIH and VA research programs for nearly two decades, with particularly deep entrenchment in the National Institute on Aging and National Institute of Environmental Health Sciences genotyping outsourcing models. The company's service portfolio—automated genotyping, DNA extraction, PCR assays, gene sequencing, multi-gene analysis, and bioinformatics database hosting with XML interface capability—supports federal breeding-colony management, transgenic animal research, and reproducibility assurance across neurology, environmental health, substance-abuse, infectious-disease, and age-related research domains, with 72-hour or faster turnaround as a standard capability.